ReviewMini reviews in medicinal chemistry2026
Phosphodiesterase 4 (PDE4) Inhibitor in Atopic Dermatitis: Impact of Nanocrisaborole on Biopharmaceutical Performance and Treatment Outcomes.
Review in Mini reviews in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The skin condition in atopic dermatitis, commonly referred to as eczema, is characterized by dry, itchy, and inflamed skin. Eczematous lesions frequently present with itching, irritation, broken skin, oozing, and crusting. Due to weakened immunity, patients with atopic dermatitis are more susceptible to developing additional conditions such as asthma and hay fever. Topical treatment of atopic dermatitis, including the use of promising PDE4 inhibitors such as crisaborole, is limited in its ability to permeate deeper into the skin due to poor physicochemical properties, including low aqueous solubility and difficulty in penetrating the epidermis. The delivery of existing therapeutics, such as crisaborole, using nanotechnology is a promising approach to overcome these limitations. Moreover, understanding the chemistry, structure-activity relationship, physicochemical properties, and stability of crisaborole is essential to ensure the quality, safety, and therapeutic efficacy of the active pharmaceutical ingredient during the development of novel pharmaceutical products. The present manuscript comprehensively discusses the significance of PDE4 inhibitors, specifically crisaborole, in the management of atopic dermatitis and the utilization of nanotechnology to evaluate its impact on biopharmaceutical performance and therapeutic outcomes. Furthermore, the detailed chemistry, structure-activity relationship, and metabolic fate of crisaborole are discussed to understand the stability of nanocrisaborole during its shelf life as a novel pharmaceutical product.
Indexed as
Identifiers
42885726What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.